Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start

Maziar Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight-loss drugs at the White House in Washington, DC on November 6, 2025.

Andrew Caballero-Reynolds | Afp | Getty Images